Bybit Goes Live With ARB Token and a $400K Prize Pool

DUBAI, UNITED ARAB EMIRATES – Media OutReach – 23 March 2023 – Bybit, the world’s third most visited crypto exchange, is proud to list the Arbitrum (ARB) token — along with a massive prize pool of $400K to celebrate. Today, users will be able to deposit ARB and trade newly created ARB spot pairs, perpetual contracts, and trading bot pairs.  

Arbitrum is the biggest player in Ethereum’s layer 2 scaling landscape, designed to boost Ethereum’s speed and scalability while adding additional privacy features. The release of ARB (which includes “airdropping” 12.75% of the entire supply to the chain’s early users) is one of the most highly-anticipated events in the cryptocurrency industry this year. 

To celebrate this occasion, Bybit has launched a series of campaigns that offers ARB traders a chance to win part of its massive $400K prize pool. 

Firstly, all users who deposit 250 ARB will receive a gift of 25 USDT, and new users who have used the Arbitrum-native trading platform GMX, can claim a further 0.5 GMX with a deposit of 500 ARB. Also, Bybit’s official Twitter account will be giving away GMX and USDT in a lucky draw to 400 users who like or retweet its tweets, or follow the official Twitter account.

Bybit offers a range of trading bots, which allow users to automate strategies, backtest them, and trade the markets 24/7. Their bots are easy to configure, so even beginners can benefit from automated trading. 

As part of the ARB celebration, users who trade ARB via Bybit’s spot grid bots will share in a $20K prize pool. Another launchpool campaign for ARB subscribers will unlock a total of $150K in rewards. Finally, a high APY ARB fixed-term product is available via Bybit Earn, allowing traders to earn even more rewards from their investments. 

“At Bybit, we recognize our responsibility to provide forward-thinking opportunities for our users and lead the way in supporting the proliferation of cryptocurrency and blockchain technology,” said Ben Zhou co-founder and CEO of Bybit. “I am delighted to see that we are offering an ARB token listing, which promises unique rewards for those who make use of it. We are eager to see how our users leverage this powerful new asset and await their feedback with enthusiasm.”

#Bybit / #NextLevelOpportunities

Further Information and Resources

About Bybit

Bybit is a cryptocurrency exchange established in 2018 that offers a professional platform where crypto traders can find an ultra-fast matching engine, excellent customer service and multilingual community support. Bybit is a proud partner of Formula One’s reigning Constructors’ and Drivers’ champions, the Oracle Red Bull Racing team, esports teams NAVI, Astralis, Alliance, Made in Brazil (MIBR), and Oracle Red Bull Racing Esports, and association football (soccer) team Borussia Dortmund.

For more information please visit:

For updates, please follow: Bybit’s Communities and Social Media 

For media inquiries, please contact:

Curia Collaborates with Corning to Advance Biopharmaceutical Continuous-Flow Development and Manufacturing Programs

Collaboration marks the first global installation of Corning’s G1 production system to support higher-quality API-chemical production using inherently safer flow-chemistry technology

ALBANY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced a collaboration with Corning Incorporated to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally. The collaboration with Corning’s Advanced-Flow™ Reactor (AFR) team includes the first installation of Corning’s G1 production system, designed for the continuous industrial production of active pharmaceutical ingredients (API).

Continuous flow chemistry is critical for the development and manufacture of pharmaceutical intermediates and APIs, and provides advantages compared with traditional batch processing. It is an inherently safer technology that delivers faster and more robust material production with a higher selectivity of desired products.

“Innovation in drug development and production calls for safety at high speed,” said Christopher Conway, president, Research & Development, Curia. “The implementation of Corning’s G1 Production Reactor at our Albany facility expands our capability to provide scalable solutions that address complex development and manufacturing requirements facing the pharmaceutical industry. Using advanced technology and standardized workflows, Curia offers continuous flow chemistry from targeted development to commercial scale globally.”

The G1 production reactor includes an updated set of dosing lines and controls that enable continuous operations and compliance to cGMP standards.

“Collaborating with an innovation-focused company like Curia will help drive advancements in the chemical-processing industry,” said Alessandra Vizza, business director, Corning Advanced-Flow Reactors. “The implementation of Corning’s G1 production system can deliver a host of benefits. The system is an inherently safer technology that will help Curia reduce time to market with higher-quality chemical and API processing, increased efficiency of chemical and API synthesis, and lower production costs.”

“Additionally, the space-saving, energy-conserving, and waste-reducing benefits of Corning’s AFR Technology may help customers reduce the environmental impact of their manufacturing business – a key attribute as the field continues to gain momentum in the U.S. and around the world,” said Vizza.

Curia’s expertise and global network of facilities, combined with Corning’s continuous flow technology, can help drive business efficiencies and, ultimately, improve patients’ lives.

About Curia
Curia is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at

About Corning Incorporated
Corning ( is one of the world’s leading innovators in materials science, with a 170-year track record of life-changing inventions. Corning applies its unparalleled expertise in glass science, ceramic science, and optical physics along with its deep manufacturing and engineering capabilities to develop category-defining products that transform industries and enhance people’s lives. Corning succeeds through sustained investment in RD&E, a unique combination of material and process innovation, and deep, trust-based relationships with customers who are global leaders in their industries. Corning’s capabilities are versatile and synergistic, which allows the company to evolve to meet changing market needs, while also helping its customers capture new opportunities in dynamic industries. Today, Corning’s markets include optical communications, mobile consumer electronics, display, automotive, solar, semiconductors, and life sciences.

Curia Contact Information:
Sue Zaranek
+1 518 512 2111

Corning Contact Information:
Sarah Pakyala
+1 607 974 4902

GlobeNewswire Distribution ID 8794440

GMAC Task Force Revamps Business Education Admissions Reporting Standards

Revision aims to support business schools in today’s ranking efforts and help prospective candidates compare programs on leveled playing field

RESTON, Va., March 23, 2023 (GLOBE NEWSWIRE) — The Graduate Management Admission Council (GMAC), a global association representing leading business schools, today released an updated version of the Graduate Management Education Admissions Reporting Standards. The revision, led by a task force of 14 GMAC member schools, aimed to ensure the standards align with the shifting landscape of graduate business education and today’s best practices of identifying gender, race and ethnicity, and undergraduate majors, among other criteria commonly used in the admissions process.

According to GMAC’s annual survey on prospective students worldwide, candidates rely heavily on school websites and rankings in their program selection process. The 2023 survey of thousands of business school aspirants – to be published early next month – shows that school websites and published program rankings were the top two factors in the decision making of individuals considering applying for graduate business degrees. Informed by this finding, GMAC believes it is vitally important that the information presented to prospective students is anchored in a common definition of the terms used by schools and various publications in collecting the data for reporting.

“This work, initiated in response to a strong desire for consistency and transparency from the business school community we serve, is being done to create trust with and among business school admissions professionals, especially those who are new to the field. Without a doubt, adopting the standardized reporting criteria at a large scale would allow prospective students and rankings organizations alike to compare apples to apples and oranges to oranges across the wide spectrum of program options available in the market today,” said Joy Jones, CEO of GMAC. “On behalf of the Council, I extend our sincerest gratitude to the task force for the time, effort, and care dedicated to revising and promoting the standards.”

“The task force invested many hours reviewing survey questionnaires and collecting data, as well as discussing proposed revisions over calls and with stakeholders at conferences, to address the tough questions from the business school community on how we can better reflect the many changes in the industry – and the society – we encounter today. For example, there is a growing acknowledgement and respect for identity preferences and an interest in segments like first generation and military students,” said Marci Armstrong, professor of practice, marketing at Southern Methodist University’s Cox School of Business and co-chair of the task force revising the standards. “Rest assured, we were fully aware of the stakes at hand and did not just rubber-stamp the new standards.”

In 2019, GMAC formed a task force to revise the MBA Reporting Criteria – first published by GMAC in 2000 and adopted by approximately 200 business schools – into Graduate Management Education Admissions Reporting Standards. The standards, subsequently endorsed by GMAC members in the summer of 2020, were meant to be revisited every two years to ensure they continue to guide business schools in distributing reliable, accurate, useful, and comparable admissions data for prospective students and rankings organizations. A new task force was organized at the beginning of 2022 to tackle the review and revision of the standards in three sections – school and program information, application process, and admissions reporting and class profile, supplemented by region and areas of study classifications.

“In the past three years – particularly in response to the global pandemic – our industry has innovated and grown tremendously. A prime example is the delivery of online programs,” said Nita Swinsick, associate dean of graduate & executive degree programs admissions at Georgetown University’s McDonough School of Business and co-chair of the task force. “While the traditional on-campus, two-year MBA remains the most sought-after graduate management degree, there are a great number of programs offering a wide range of flexibility and length and still lead to successful business careers.”

“GMAC will continue to be a steward of the standards and will publish a list of schools and corresponding programs that decide to adopt and remain in compliance with the standards. Adopting and complying schools can also receive a badge from GMAC for use in their outreach materials to signal to candidates, ranking publishers and other stakeholders their compliance with the standards,” said Sabrina White, vice president of school and industry engagement at GMAC. “It is our hope that more members of the business school community – as well as ranking publishers – will begin leveraging these standards to benefit the people aspiring to better themselves and the world through graduate management education.”

Business schools, ranking agencies and other stakeholders worldwide that wish to obtain a copy of or start adopting the latest reporting standards may reach out to GMAC at

About GMAC

The Graduate Management Admission Council (GMAC) is a mission-driven association of leading graduate business schools worldwide. GMAC provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry as well as resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment.

More than 12 million prospective students a year trust GMAC’s websites, including, to learn about MBA and business master’s programs, connect with schools around the world, prepare and register for exams and get advice on successfully applying to MBA and business master’s programs. BusinessBecause and The MBA Tour are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
Mobile: 202-390-4180 

GlobeNewswire Distribution ID 8794409

Anglepoint Launches ServiceNow App: IBM Licensing for Software Asset Management

The App Provides Enhanced Abilities to Discover and Classify IBM Products

SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2023 / Anglepoint, the leading Software Asset Management (SAM) services provider to the Fortune 500 and Global 2000, has launched its first app on the ServiceNow app store, IBM Licensing for Software Asset Management. This app, combined with Anglepoint’s IBM Managed Service, offers the ability to identify, measure, and track IBM’s software natively within ServiceNow. The app is available now in the ServiceNow Store as part of the ServiceNow “Utah” release and is a companion app to ServiceNow’s IBM License Compliance for Software Asset Management app.For customers who are also under IBM’s Authorized SAM Provider program (IASP) with an Anglepoint managed service, IBM may accept this solution as a replacement to ILMT for sub-capacity reporting.

Anglepoint Vice President Mari Petersen says, “As a leader in the Gartner Magic Quadrant three years in a row, Anglepoint is the premier organization to provide solutions to our clients that best meet their needs and benefit their ITAM Programs. For organizations who have or are considering investing in the ServiceNow platform and services for IBM software asset management, this app is the obvious solution. Connecting Anglepoint’s unparalleled expertise in IBM licensing with the power of the ServiceNow solution provides customers with the opportunity to understand how to optimize their IBM software licensing spend.”

Key features and benefits of the IBM Licensing for Software Asset Management app include:

  • Measure IBM sub-capacity (under the IASP program only)
  • Access IBM licensing expertise
  • Simplify license management
  • Gain confidence and visibility of IBM assets within ServiceNow SAMP
  • Identify opportunities for cost reduction

The launch of the app in partnership with ServiceNow provides IBM customers a solution that leverages the full power of the ServiceNow platform.

To access the free app, customers will need to be using the newest version of ServiceNow “Utah” and engage with Anglepoint for an IBM Managed Service. To learn more about this solution, please contact Anglepoint at


Anglepoint is the leading provider of Software Asset Management & Technology Asset Management services to the Fortune 500 & Global 2000. Anglepoint’s services drive cost optimization, risk mitigation & strategic planning within the cloud, SaaS, enterprise software & hardware estates of complex hybrid IT environments. Anglepoint delivers comprehensive managed services, including SAM strategy, execution, process automation, and technology selection & implementation.

Connect with Anglepoint on LinkedIn, Facebook, Twitter, and

Contact Information

Alison Frederick
Director of Analyst Relations and Client Experience

SOURCE: Anglepoint

UNFI EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages United Natural Foods, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – UNFI

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of United Natural Foods, Inc. (NYSE: UNFI) between March 10, 2021 and March 7, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2023.

SO WHAT: If you purchased United Natural Foods securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the United Natural Foods class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) that, despite its cost saving Value Path initiative, United Natural Foods had not invested in improving its data management and related infrastructure; (2) that, as a result, the Company could not respond adequately to cost changes, such as inflationary pressure; (3) that, as a result, the Company could not appreciate the benefits of procurement gains and inventory gains achieved during fiscal 2022; (4) that, as a result of the foregoing, the Company’s profitability would be materially adversely impacted; and (5) and that as a result of the foregoing, Defendant’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the United Natural Foods class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn:, on Twitter: or on Facebook:

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827

GlobeNewswire Distribution ID 8793630

Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating Results


Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Completed all 115 implants in the DREAM U.S. pivotal study

Mont-Saint-Guibert, Belgium – March 22, 2023 09:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year 2022.

Recent Financial and Operating Highlights

  • Completed all 115 implants in the DREAM U.S. pivotal trial, with 12-month data expected early next year.
  • Filed the first module in the modular PMA submission.
  • Submitted 12-month data1 on the first 34 DREAM patients as a late-breaking abstract to SLEEP 2023 demonstrating a 65% AHI responder rate, a 76% ODI responder rate and safety in-line with expectations. These data are preliminary and not conclusive of final DREAM success.
  • Achieved quarterly sales of €1.3 million resulting in a sequential German market share gain.
  • Ended the year with 38 active German accounts, up from 12 entering 2022.
  • Strengthened supply chain with Belgium manufacturing facility receiving clearance from the EU notified body.
  • Implanted the first patients in the ACCCESS U.S. IDE pivotal study to treat complete concentric collapse (CCC). Implant completion expected in 2024.
  • Total cash position of €94.8 million at the end of 2022.

2023 Key Objectives

  • Focus on patient follow up in the DREAM study resulting in reaching the primary endpoints.
  • U.S. regulatory, manufacturing and market access readiness.
  • Drive further revenue and market share growth in Germany.

“With all 115 implants completed in the DREAM study and our first PMA module submitted, we achieved key milestones towards U.S. FDA approval. Our attention now focuses on patient follow up. With the clearance of our second manufacturing site, we have strengthened our supply chain to meet increasing demand,” commented Olivier Taelman, Nyxoah Chief Executive Officer.

Mr. Taelman continued, “Commercially in Europe, we are excited to see the continued demand growth for Genio in Germany. Our growing experience with CCC patients in Europe, driven by our expanded label, reinforces our confidence in our ongoing U.S. ACCCESS study.”

Fourth Quarter and Full Year 2022 Results


For the three months ended December 31,  For the year ended December 31,
2022 2021 2022 2021
Revenue €1,307 €295 €3,084 €852
Cost of goods sold (465) (105) (1,150) (303)
Gross profit 842   190 1,934   549
Research and Development Expense (4,575) (3,335) (15,861) (12,344)
Selling, General and Administrative Expense (5,363) (3,937) (18,855) (14,712)
Other income/(expense) 46 539 283 265
Operating loss for the period (9,050)   (6,543) (32,499) (26,242)
Financial income (4,609) 3,603 6,763 3,675
Financial expense 1,153 (588) (4,320) (2,072)
Loss for the period before taxes (12,506) (3,528) (30,056) (24,639)
Income taxes (790) (2,720) (1,169) (2,980)
Loss for the period (13,296) (6,248) (31,225) (27,619)
Loss attributable to equity holders (13,296) (6,248) (31,225) (27,619)
Other comprehensive income/(loss)
Items that may not be subsequently reclassified to profit or loss (net of tax)
Remeasurements of post-employment benefit obligations, net of tax 70 (68) 70 (68)
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences (82) (17) (96) 121
Total other comprehensive income/(loss) (12)   (85)   (26)   53
Total comprehensive loss for the year, net of tax (13,308) (6,333) (31,251) (27,566)
Loss attributable to equity holders (13,308)   (6,333)   (31,251)   (27,566)
Basic loss per share (in EUR) €(514) €(238) €(1,209) €(1,161)
Diluted loss per share (in EUR) €(514) €(238) €(1,209) €(1,161)

DECEMBER 31, 2021 (in thousands)

As of December 31,
2022 2021
Non-current assets
Property, plant and equipment €2,460 €2,020
Intangible assets 39,972 25,322
Right of use assets 3,159 3,218
Deferred tax asset 47 46
Other long-term receivables 173 164
45,811 30,770
Current assets
Inventory 882 346
Trade receivables 1,463 226
Other receivables 1,775 2,286
Other current assets 1,284 1,693
Financial assets 76,968
Cash and cash equivalents 17,888 135,509
  100,260 140,060
Total assets 146,071   170,830
Capital and reserves
Capital 4,440 4,427
Share premium 228,275 228,033
Share based payment reserve 5,645 3,127
Other comprehensive income 176 202
Retained loss (118,212) (87,167)
Total equity attributable to shareholders 120,324 148,622
Non-current liabilities
Financial debt 8,189 7,802
Lease liability 2,586 2,737
Pension liability 80
Provisions 59 12
Deferred tax liability 5
  10,834   10,636
Current liabilities
Financial debt 388 554
Lease liability 719 582
Trade payables 4,985 3,995
Current tax liability 3,654 2,808
Other payables 5,167 3,633
  14,913 11,572
Total liabilities 25,747   22,208
Total equity and liabilities 146,071 170,830


Revenue was €1.3 million for the fourth quarter ending December 31, 2022, compared to €295,000 for the fourth quarter ending December 31, 2021. Revenue for the full year of 2022 was €3.1 million, compared to €0.9 million for the full year of 2021. The increase in revenue was attributable to the Company’s commercialization of the Genio® system, primarily in Germany.

Cost of Goods Sold

Cost of goods sold was €465,000 for the three months ending December 31, 2022, representing a gross profit of €0.8 million, or gross margin of 64.4%. This compares to total cost of goods sold of €105,000 in the fourth quarter of 2021, for a gross profit of €190,000, or gross margin of 64.4%.

For the full year ending December 31, 2022, total cost of goods sold was €1.2 million, representing a gross profit of €1 million, or gross margin of 62.7%. This compares to total cost of goods sold of €303,000 for the full year of 2021, for a gross profit of €0.5 million or gross margin of 64.4%.

Research and Development Expenses

Research and development expenses were €4.6 million for the three months ending December 31, 2022, versus €3.3 million for the prior year period, reflecting the Company’s investments in the development of next generation versions of the Genio® system as well as ongoing clinical studies, most notably DREAM in the U.S.

For the full year ending December 31, 2022, research and development expenses were €15.9 million, versus €12.3 million for the full year of 2021.

Selling, General and Administrative Expenses

Selling, general and administrative expenses rose to €5.4 million for the fourth quarter of 2022, up from €3.9 million in the fourth quarter of 2021. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah’s corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.

For the full year ending December 31, 2022, selling, general and administrative expenses were €18.9 million, up from €14.7 million for the full year 2021 due to increased commercial efforts in Germany and investments in Nyxoah’s corporate infrastructure.

Operating Loss

Total operating loss for the fourth quarter and full year 2022 was €9.1 million and €32.5 million, respectively, versus €6.5 million and €26.2 million in the fourth quarter and full year 2021, respectively. This was driven by the acceleration in the Company’s R&D spending, as well as ongoing commercial and clinical activities.

Cash Position
As of December 31, 2022, cash and financial assets totaled €95 million, compared to €135.5 million on December 31, 2021. Total cash burn was approximately €3.4 million per month during 2022.

Full year report 2022
Nyxoah’s financial report for the full year of 2022, including details of the audited consolidated results, are available on the investor page of Nyxoah’s website (

Conference call and webcast presentation
Nyxoah will conduct a conference call open to the public today at 10:30pm CET / 4:30pm ET, which will also be webcast. To participate in the conference call, please access the following link to register for a dial-in number:

A question-and-answer session will follow the presentation of the results. To access the live webcast, go to The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

David DeMartino, Chief Strategy Officer
+1 310 310 1313

1 For the trial to be successful, of the 115 patients, at least 63% of patients need to be AHI and ODI responders at the 12-month follow-up.


GlobeNewswire Distribution ID 1000799654

In a meeting with Zimbabwe’s vice president, Foreign Minister Malki calls for fighting colonialism

In a meeting with Vice President of the Republic of Zimbabwe Constantino Chiwenga, Minister of Foreign Affairs and Expatriates Riyad al-Malki called for the continuation of joint action to combat colonialism and to enhance cooperation to support the resilience of the Palestinian people.

Malki briefed Chiwenga in their meeting in Harare on the latest political developments and the systematic Israeli violations against the Palestinian people, their land and holy places.

He said that the Palestinian people are facing a racist, Nazi government that encourages violence and hatred, referring to the statements of the extremist Israeli cabinet minister Bezalel Smotrich, in which he called for wiping out the town of Hawara and denying the existence of the Palestinian people.

Malki said the adherence of the Zimbabwean people and the defense of their land in the face of colonialism is an example to follow, stressing Palestine’s rejection of the illegal sanctions imposed on Zimbabwe.

He said Palestine is ready to dispatch experts and professionals needed by Zimbabwe to share their experiences and knowledge and to engage in joint development programs and activities, especially in the fields of agriculture, health, information technology, education, media, and others.

For his part, Chiwenga praised the strong relationship between the two countries and said that the people of Zimbabwe feel the suffering of the Palestinian people, and understand their struggle and steadfastness in the face of the occupying oppressor.

He denounced Israel’s racist and barbaric policies against the Palestinian people, their land and property, stressing that his country will continue to support the Palestinian cause and the legitimate right of the Palestinian people to self-determination and the establishment of their independent state.

The two sides discussed several issues of common concern and discussed new ways of cooperation in the interest of the two peoples, such as exchanging official visits and deepening bilateral relations in various development fields.

Chiwenga thanked the State of Palestine for the programs implemented by the Palestinian International Cooperation Agency (PICA) for the benefit of Zimbabwean institutions in 2019 and appreciated the proposals put forward to send Palestinian experts to Zimbabwe in the agricultural, health and media fields.

He conveyed the greetings of his government to the President of the State of Palestine, Mahmoud Abbas, the government, and the Palestinian people, and affirmed its readiness to develop the bilateral relationship in different fields.

Source: Palestine News & Information Agency

Weather: Partly cloudy with a rise in temperature becoming 2°C above the seasonal average

A rise in temperature is expected today in Palestine, the first day of the Muslim holy fast month of Ramadan, approaching 2°C above the seasonal average with partly cloudy to cloudy skies and warm conditions, according to the Palestinian Meteorological Department (PMD).

Winds are southwesterly to northwesterly, light to moderate, and sea waves are low.

Temperature in the capital, Jerusalem, and Bethlehem is expected to reach a high of 19°C and a low of 13°C and in Ramallah and Hebron a high of 18°C and a low of 12°C. In Jericho, the Dead Sea, and the Jordan Valley temperature is expected to reach a high of 28°C and a low of 18°C, while it is expected to reach a high of 23°C and a low of 16°C in Gaza and the coastal areas.

An additional rise in temperature is expected tomorrow, Friday, approaching 4°C above the seasonal average. A chance of scattered rain is expected during the night.

Saturday’s temperature is set to plummet as sporadic rain showers are expected accompanied by occasional thunderstorms.

A significant drop in temperature is expected for Sunday to become 4°C below the seasonal average. Sporadic rain and possibly thunderstorms are expected in most areas of Palestine, said the PMD.

Source: Palestine News & Information Agency

Palestinian freedom fighters incarcerated in Israel suspend hunger strike after conceding to their demands

Palestinian freedom fighters incarcerated in Israel for their resistance of the occupation last night suspended a hunger strike that was planned to start today after the Israel Prison Services (IPS) conceded to their demands and stopped all punitive and arbitrary measures against them.

The Commission of Detainees and Ex-Detainees Affairs and the Palestinian Prisoner’s Society said in a brief statement that the prisoners decided to suspend the hunger strike after the IPS decided, following a long meeting with representatives of the prisoners, to cancel all punitive measures imposed against them called for by the fascist Israeli cabinet minister Itamar Ben Gvir.

The freedom fighters have declared a mutiny against prisoner rules since 4 February following the implementation of repressive measures against them.

As part of their struggle against these measures, 2,000 prisoners were supposed to go on a hunger strike on the first day of the holy month of Ramadan, which coincides today.

The measures imposed by the IPS on the prisoners included controlling the amount of water they use, reducing the duration of showering so that prisoners are allowed to shower at a specific hour, and locking bathrooms designated for showering in some prisons.

Also among the measures is providing the prisoners with bad bread and in some prisons the IPS provided them with frozen bread, as well as doubling the raids and searches against them using stun grenades and sniffer dogs.

Among them also is the approval in a preliminary reading of a draft law depriving prisoners of medical treatment and some surgical operations, and the approval of the Ministerial Legislative Committee in the Israeli government of a draft law approving capital punishment for prisoners involved in the armed resistance.

The IPS also imposed other repressive measures, including doubling the solitary confinement of prisoners, removing television sets from some sections where detainees are held, escalating transfers of the leaders of the prisoners’ movement, particularly those serving life terms, and threatening in some central prisons to close public facilities on Fridays and Saturdays, as was the case in the Naqab (Negev) prison.

More than 4,780 freedom fighters are currently incarcerated in Israel, including 29 female prisoners and 160 minors.

Source: Palestine News & Information Agency

Palestinian shot and killed during an Israeli army raid of a village near Tulkarm

A 25-year-old Palestinian man identified as Amir Imar Abu Khadijeh was shot and killed this morning during an Israeli army raid and siege of his house in the village of Izbat Shoufa, southeast of the northern West Bank city of Tulkarm.

The Ministry of Health said Abu Khadijeh was brought to hospital in Tulkarm after he was hit by a bullet in the head that led to a complete laceration of the skull and forced the brain out of his head. He was also shot in the lower extremities.

Murad Droubi, a local activist, said a large Israeli army force raided the village, closed its main entrance and prevented movement of people and cars while the force surrounded a house in the village.

Witnesses said gunfire was heard during the siege of the house that resulted in the killing of Abu Khadijeh.

The Israeli occupation forces have killed 87 Palestinians since the start of the year, including 17 minors, two elderly men, and one woman.

Source: Palestine News & Information Agency

Newspapers Review: Palestinian freedom fighters suspending hunger strike highlight of the dailies

The decision of the Palestinian freedom fighters incarcerated in Israel to suspend their hunger strike after the Israel Prison Services conceded to their demands was highlighted on the front page of the three Palestinian Arabic dailies published today.

They said in their main front-page story that the prisoners succeeded in forcing the prison services to stop all measures against them.

Al-Hayat al-Jadida daily said that President Mahmoud Abbas has made extensive contacts to put a halt to Israeli aggression against the Palestinian people and prisoners.

It also quoted Prime Minister Mohammad Shtayyeh saying that by canceling the Disengagement Law, Israel is actually re-occupying the West Bank.

It also said dozens of injuries, arrests and demolition orders were documented in the occupied territories.

Al-Quds daily said the occupation authorities issued demolition orders against 20 homes and facilities in the West Bank.

It quoted nine countries members of the United Nations Security Council saying in a statement that the Israeli settlements in the occupied territories are illegal and that they are ready to support any peace initiative.

The paper also said the United States reprimanded the Israeli ambassador to Washington over the decision to cancel the Disengagement Law.

It said more than 200,000 people have called on Israel to end its apartheid system against the Palestinians.

Al-Ayyam daily said the West Jerusalem Israeli municipality is speeding up the construction of a 1200-unit settlement in the south of occupied East Jerusalem.

It said the Lawyers Union have stopped all protest measures and resumed work after reaching an agreement with the Palestinian government, while the teachers continue their strike demanding better pay from the government.

Source: Palestine News & Information Agency

Israeli occupation forces detain at least 12 Palestinians in raids at their homes in the occupied territories

The Israeli occupation forces today detained at least 12 Palestinians in raids at their homes across the occupied territories, according to various sources.

In the Jerusalem area, forces detained two siblings in a raid at their home in al-Ram town, north of the occupied city.

In Ramallah, soldiers detained a wounded youth in the town of Beit Sira, west of Ramallah city.

Soldiers also detained a Palestinian youth in the village of Beir al-Basha, southwest of the city of Jenin, another during a raid and siege of a house in Izbat Shoufa village, southeast of Tulkarm city, during which a 25-year-old Palestinian was shot and killed in the same raid, and three others from the Nablus district, in the north of the West Bank.

In the south of the West Bank, soldiers detained a 17-year-old minor in a raid at Wad Rahhal village, south of Bethlehem, and three men, including a man and his son, in the city of Hebron.

Source: Palestine News & Information Agency